

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	L10V <sup>K7%</sup> <sub>cons=9,728</sub> • T12S <sup>K1%</sup> <sub>cons=11,415</sub> • I13V <sup>D20%</sup> <sub>cons=12,081</sub> • G16E <sup>K7%</sup> <sub>cons=11,158</sub> • E35D <sup>T1%</sup> <sub>cons=14,185</sub> • M36I <sup>D20%</sup> <sub>cons=14,147</sub> • R41K <sup>V9%</sup> <sub>cons=14,185</sub> • R57K <sup>V9%</sup> <sub>cons=11,171</sub> • L63T <sup>T1%</sup> <sub>cons=11,728</sub> • H69K <sup>V7%</sup> <sub>cons=14,811</sub> • L89M <sup>D20%</sup> <sub>cons=12,162</sub>	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
PR comments		
Other		
• L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.		

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

NRTI Mutations:	None
NNRTI Mutations:	None
RT Other Mutations:	K11T <sup>V9%</sup> <sub>cons=8,794</sub> • V21I <sup>D20%</sup> <sub>cons=7,812</sub> • V35MT <sup>T=147%, M=38%</sup> <sub>cons=6,431</sub> • T39R <sup>V9%</sup> <sub>cons=6,431</sub> • V60I <sup>K7%</sup> <sub>cons=6,175</sub> • D121DH <sup>N=40%, D=14%</sup> <sub>cons=6,180</sub> • K122E <sup>V9%</sup> <sub>cons=6,108</sub> • D123DN <sup>N=14%, D=41%</sup> <sub>cons=6,205</sub> • I135IT <sup>L=40%, T=42%</sup> <sub>cons=7,238</sub> • K173A <sup>T1%</sup> <sub>cons=7,962</sub> • D177E <sup>V9%</sup> <sub>cons=7,285</sub> • V179W <sup>L=10%, L=41%</sup> <sub>cons=7,210</sub> • T200TA <sup>T=147%, L=41%</sup> <sub>cons=8,142</sub> • I202V <sup>V9%</sup> <sub>cons=6,007</sub> • Q207A <sup>V9%</sup> <sub>cons=5,119</sub> • R211K <sup>V9%</sup> <sub>cons=6,204</sub> • V245Q <sup>V7%</sup> <sub>cons=2,171</sub> • E248D <sup>V9%</sup> <sub>cons=2,127</sub> • K281R <sup>V9%</sup> <sub>cons=801</sub> • T286A <sup>V9%</sup> <sub>cons=801</sub> • E291D <sup>V7%</sup> <sub>cons=541</sub> • I293V <sup>V9%</sup> <sub>cons=408</sub> • P294T <sup>V9%</sup> <sub>cons=408</sub> • E312D <sup>V7%</sup> <sub>cons=212</sub>
Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Susceptible
efavirenz (EFV)	Susceptible
etravirine (ETR)	Susceptible
nevirapine (NVP)	Susceptible
rilpivirine (RPV)	Susceptible

RT comments			
Other			
• V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.			

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.